Tamiflu Pediatric Adverse Events: Questions and Answers

General Meeting Questions: Why are certain drugs having their safety reports presented to the Pediatric Advisory Committee on November 18, 2005? The eight products being reviewed are presently due for a public discussion of their adverse events as required by Section 17 of the Best Pharmaceuticals for Children Act (BPCA). BPCA mandates the review of the adverse event reports received during the on

[send]

FDA

[stella_nf]

FDAのタミフル記事

[AFCP]

FDA